Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
GRM by Grunenthal for Inflammation: Likelihood of Approval
GRM is under clinical development by Grunenthal and currently in Phase I for Inflammation. According to GlobalData, Phase I drugs...
Data Insights
Capsaicin by Grunenthal for Chemotherapy Induced Peripheral Neuropathy: Likelihood of Approval
Capsaicin is under clinical development by Grunenthal and currently in Phase III for Chemotherapy Induced Peripheral Neuropathy. According to GlobalData,...